Vimta Labs Limited — Q1FY27 Earnings Call Summary

VIMTALABS · Q1FY27 · Filed 24 Jul 2026

Key Takeaways

• Electronics testing stable; defense budget increase of 15.19% expected to boost demand
• Capex planned INR80 crores for FY27, including INR10 crores remaining for biologics
• Q1 FY27 total income INR1,129 million +13.7% y-y; EBITDA INR411 million +16% y-y; EBITDA margin 36.4%; PAT INR210 million +11.4% y-y; PAT margin 18.6%
• Margins expected to sustain; operating margin moderated q-o-q due to facility expenses and currency appreciation
• Customer retention rate above 90%; infrastructure capacity built for next 4-5 years
• Pharma contract research and testing showed stable sequential revenue with strong y-y growth; clinical research recovering
• Food testing declined due to global import-export challenges; focus shifted to domestic market
• Biologics vertical operational with first order secured; commercialization started in Q1
• Export revenue contribution about 40%, mainly from US pharma services
• Management confident on maintaining growth momentum despite near-term headwinds

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.